AN2 Therapeutics (ANTX) Income Statement: Revenue & Earnings

AN2 Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

AN2 Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	40.49	54.87	29.51	16.91	6.02
Selling, General & Administrative	14.07	14.76	12.75	4.67	1.27
Operating Expenses	54.55	69.64	42.26	21.57	7.28
Operating Income	-54.55	-69.64	-42.26	-21.57	-7.28
Other Income/Expense
Interest Income	5.47	4.86	1.35	0.07	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	3.23	0.04	1.31	-0.04	-6.32
Income
Income Before Tax	-51.32	-64.73	-40.96	-21.54	-13.60
Income Tax Expense	0.00	-4.92	-0.30	0.00	0.00
Net Income	-51.32	-64.73	-40.96	-21.54	-13.60
Net Income - Continuous Operations	-51.32	-64.73	-40.96	-21.54	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	3.23	-69.65	-42.26	-21.57	0.00
EBIT	-54.55	-69.64	-42.26	-21.57	-7.28
Depreciation & Amortization	54.55	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-2.00	-3.00	-3.00	-11.00	-6.00
Diluted EPS	-2.00	-3.00	-3.00	-11.00	-6.00
Basic Shares Outstanding	29.83	23.60	15.34	2.64	2.57
Diluted Shares Outstanding	29.83	23.60	15.34	2.64	2.57